HOME >> BIOLOGY >> NEWS
Accentia Biopharmaceuticals announces option agreement with Mayo

(NASDAQ : ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education and Research for the exclusive right to negotiate a license for a method of use for any and all antifungals other than amphotericin B applied intranasally for the treatment of chronic sinusitis, sometimes known as chronic rhinosinusitis. If unexercised, the option expires on December 6, 2006. Accentia has previously obtained a worldwide exclusive license for the method of use, utilizing the antifungal, amphotericin B, for this indication. Accentia is developing a unique formulation of amphotericin B for intranasal application for the treatment of chronic sinusitis under an Investigational New Drug Application (IND).

Chronic sinusitis affects an estimated 31 million Americans. The symptoms are three or more months of chronic nasal obstruction, nasal discharge, and periocular headaches or pressure sensation. The symptoms of chronic inflammation could include the growth of inflammatory polyps in the nose, and recurrent bouts of acute bacterial sinusitis. There is no approved pharmaceutical for the indication of chronic sinusitis. Many patients with severe disease resort to sinus surgery in an attempt to relieve nasal obstruction and improve sinus drainage. The Mayo Clinic researchers have identified a ubiquitous air-borne fungus in the mucus of the nose and sinuses that elicits an inflammatory response in susceptible patients. Published studies at the Mayo Clinic and elsewhere have demonstrated a significant improvement in signs and symptoms of chronic sinusitis in patients treated with intranasal amphotericin B.

"We are working diligently to develop the Mayo patented technology for the treatment of chronic sinusitis with intranasal amphotericin B," said Steve Arikian, MD, President and COO of Accentia's Product Development and Market Services. "We recognized that our impending clinical trials of amphotericin B for this indication, if
'"/>

Contact: Sherran Brewer
sbrewer@accentia.net
866-481-9020
SciWords
15-Dec-2005


Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. AutovaxID-C introduced by Accentia Biopharmaceuticals
3. Accentia Biopharmaceuticals acquires exclusive license
4. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
5. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
6. ESA announces 2007 award recipients
7. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
8. Conservation Leadership Program announces 2007 awardees
9. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
10. Revolutionary global environment fund announces $50M expansion
11. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2020)... ... February 04, 2020 , ... ... (USPTO) issued the company a second patent related to proprietary liquid crystal technology ... compliments another patent from the USPTO issued on December 3, 2019. Together, these ...
(Date:1/29/2020)... ... January 29, 2020 , ... INDIGO Biosciences, Inc. (INDIGO), the ... announced a record earnings year for 2019. With final numbers to be released ... percent increase in revenue and a thirty percent increase in gross profit, and ...
(Date:1/27/2020)... DIEGO (PRWEB) , ... January 27, 2020 , ... ... Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former senior ... as Executive Chairman of Broadline Capital, the global alternative investment firm. , ...
Breaking Biology News(10 mins):
(Date:2/3/2020)... ... February 03, 2020 , ... ... Cambridge, MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype ... a best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping from ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cerebyte, the leader in ... computing, today announced the availability of neuroscience of transformational leadership workshops. These highly ... neuroscience of leadership and change research to become great transformational leaders. The ...
(Date:1/24/2020)... ... 2020 , ... Sierra Instruments, global leader in mass flow, ... ideal for BioPharm OEMS. Sierra also announces RedyCompact™ flow meters and ... high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable no-drift CMOS (Complementary ...
(Date:1/22/2020)... ... 2020 , ... COBO Technologies and Cardea Bio partner to ... agreed to co-develop and market a portfolio of CRISPR QC products and services ... longer-term, the parties aim to develop a COBO branded QC device based on ...
Breaking Biology Technology:
Cached News: